112 related articles for article (PubMed ID: 38678985)
1. Determination of optimum levels of binding antibody units (BAU) of new quantitative chemiluminescent immuno-assay (CLIA) in COVID-19 vaccinated volunteer blood donors.
Tiwari AK; Aggarwal G; Kale P; Yadav N; Kumar V; Singh G; Cheirmaraj K; Krishnan K
Transfus Apher Sci; 2024 Jun; 63(3):103937. PubMed ID: 38678985
[TBL] [Abstract][Full Text] [Related]
2. Chemiluminescence Immunoassay Based Serological Immunoassays for Detection of SARS-CoV-2 Neutralizing Antibodies in COVID-19 Convalescent Patients and Vaccinated Population.
Yin Q; Zhang Y; Lian L; Qu Y; Wu W; Chen Z; Pei R; Chen T; Sun L; Li C; Li A; Li J; Li D; Wang S; Guan W; Liang M
Viruses; 2021 Jul; 13(8):. PubMed ID: 34452373
[TBL] [Abstract][Full Text] [Related]
3. Anti-Spike Protein Assays to Determine SARS-CoV-2 Antibody Levels: a Head-to-Head Comparison of Five Quantitative Assays.
Perkmann T; Perkmann-Nagele N; Koller T; Mucher P; Radakovics A; Marculescu R; Wolzt M; Wagner OF; Binder CJ; Haslacher H
Microbiol Spectr; 2021 Sep; 9(1):e0024721. PubMed ID: 34190591
[TBL] [Abstract][Full Text] [Related]
4. Can commercial automated immunoassays be utilized to predict neutralizing antibodies after SARS-CoV-2 infection? A comparative study between three different assays.
Ismail A; Shurrab FM; Al-Jighefee HT; Al-Sadeq DW; Qotba H; Al-Shaar IA; Yassine HM; Abu-Raddad LJ; Nasrallah GK
Front Biosci (Landmark Ed); 2021 Jul; 26(7):198-206. PubMed ID: 34340267
[No Abstract] [Full Text] [Related]
5. Serological anti-SARS-CoV-2 neutralizing antibodies association to live virus neutralizing test titers in COVID-19 paucisymptomatic/symptomatic patients and vaccinated subjects.
Cristiano A; Nuccetelli M; Pieri M; Sarubbi S; Pelagalli M; Calugi G; Tomassetti F; Bernardini S
Int Immunopharmacol; 2021 Dec; 101(Pt B):108215. PubMed ID: 34649115
[TBL] [Abstract][Full Text] [Related]
6. SARS-CoV-2 Virus-Like Particle Neutralizing Capacity in Blood Donors Depends on Serological Profile and Donor-Declared SARS-CoV-2 Vaccination History.
Drews SJ; Hu Q; Samson R; Abe KT; Rathod B; Colwill K; Gingras AC; Yi QL; O'Brien SF
Microbiol Spectr; 2022 Feb; 10(1):e0226221. PubMed ID: 35171006
[TBL] [Abstract][Full Text] [Related]
7. Correlation of sample-to-cut-off ratio of anti-SARS-CoV-2 IgG antibody chemiluminescent assay with neutralization activity: a prospective multi-centric study in India.
Tiwari AK; Negi G; Jaiswal RM; Aggarwal G; Yadav N; Kumar V; Kulathu K
ISBT Sci Ser; 2021 Nov; 16(4):269-275. PubMed ID: 34548879
[TBL] [Abstract][Full Text] [Related]
8. The Safety and Immunogenicity of the mRNA-BNT162b2 SARS-CoV-2 Vaccine in Hemodialysis Patients.
Zitt E; Davidovic T; Schimpf J; Abbassi-Nik A; Mutschlechner B; Ulmer H; Benda MA; Sprenger-Mähr H; Winder T; Lhotta K
Front Immunol; 2021; 12():704773. PubMed ID: 34220867
[TBL] [Abstract][Full Text] [Related]
9. Predicting the protective humoral response to a SARS-CoV-2 mRNA vaccine.
Meschi S; Matusali G; Colavita F; Lapa D; Bordi L; Puro V; Leoni BD; Galli C; Capobianchi MR; Castilletti C;
Clin Chem Lab Med; 2021 Nov; 59(12):2010-2018. PubMed ID: 34492749
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of the correlation between the access SARS-CoV-2 IgM and IgG II antibody tests with the SARS-CoV-2 surrogate virus neutralization test.
Kitagawa Y; Imai K; Matsuoka M; Fukada A; Kubota K; Sato M; Takada T; Noguchi S; Tarumoto N; Maesaki S; Takeuchi S; Maeda T
J Med Virol; 2022 Jan; 94(1):335-341. PubMed ID: 34524695
[TBL] [Abstract][Full Text] [Related]
11. Long-Term Humoral Immune Response against SARS-CoV-2 after Natural Infection and Subsequent Vaccination According to WHO International Binding Antibody Units (BAU/mL).
Ruetalo N; Flehmig B; Schindler M; Pridzun L; Haage A; Reichenbächer M; Kirchner T; Kirchner T; Klingel K; Ranke MB; Normann A
Viruses; 2021 Nov; 13(12):. PubMed ID: 34960605
[TBL] [Abstract][Full Text] [Related]
12. Kinetics and ability of binding antibody and surrogate virus neutralization tests to predict neutralizing antibodies against the SARS-CoV-2 Omicron variant following BNT162b2 booster administration.
Simon G; Favresse J; Gillot C; Closset M; Catry É; Dogné JM; Douxfils J; Wieërs G; Bayart JL
Clin Chem Lab Med; 2023 Sep; 61(10):1875-1885. PubMed ID: 37078220
[TBL] [Abstract][Full Text] [Related]
13. Rapid Quantitative Point-Of-Care Diagnostic Test for Post COVID-19 Vaccination Antibody Monitoring.
Moeller ME; Engsig FN; Bade M; Fock J; Pah P; Soerensen AL; Bang D; Donolato M; Benfield T
Microbiol Spectr; 2022 Apr; 10(2):e0039622. PubMed ID: 35357223
[TBL] [Abstract][Full Text] [Related]
14. Correlation of SARS-CoV-2 Viral Neutralizing Antibody Titers with Anti-Spike Antibodies and ACE-2 Inhibition among Vaccinated Individuals.
Grunau B; Prusinkiewicz M; Asamoah-Boaheng M; Golding L; Lavoie PM; Petric M; Levett PN; Haig S; Barakauskas V; Karim ME; Jassem AN; Drews SJ; Sediqi S; Goldfarb DM
Microbiol Spectr; 2022 Oct; 10(5):e0131522. PubMed ID: 36121252
[TBL] [Abstract][Full Text] [Related]
15. SARS-CoV-2 mRNA vaccine BNT162b2 triggers a consistent cross-variant humoral and cellular response.
Mileto D; Fenizia C; Cutrera M; Gagliardi G; Gigantiello A; De Silvestri A; Rizzo A; Mancon A; Bianchi M; De Poli F; Cuomo M; Burgo I; Longo M; Rimoldi SG; Pagani C; Grosso S; Micheli V; Rizzardini G; Grande R; Biasin M; Gismondo MR; Lombardi A
Emerg Microbes Infect; 2021 Dec; 10(1):2235-2243. PubMed ID: 34749573
[TBL] [Abstract][Full Text] [Related]
16. Diagnostic performance between in-house and commercial SARS-CoV-2 serological immunoassays including binding-specific antibody and surrogate virus neutralization test (sVNT).
Winichakoon P; Wipasa J; Chawansuntati K; Salee P; Sudjaritruk T; Yasri S; Khamwan C; Peerakam R; Dankai D; Chaiwarith R
Sci Rep; 2023 Jan; 13(1):34. PubMed ID: 36593231
[TBL] [Abstract][Full Text] [Related]
17. The role of neutralizing antibodies by sVNT after two doses of BNT162b2 mRNA vaccine in a cohort of Italian healthcare workers.
Infantino M; Manfredi M; Stacchini L; Cosma C; Grossi V; Lari B; Russo E; Amedei A; Benucci M; Veneziani F; Casprini P; Catalano CM; Cirrincione G; Bonaccorsi G; Pompetti A
Clin Chem Lab Med; 2022 May; 60(6):934-940. PubMed ID: 35303766
[TBL] [Abstract][Full Text] [Related]
18. A new testing platform using fingerstick blood for quantitative antibody response evaluation after SARS-CoV-2 vaccination.
Du J; Zhang D; Pathakamuri JA; Kuebler D; Yang Y; Loginova Y; Chu E; Madej R; Neves JV; Singer B; Radke H; Spencer N; Rizk E; Zhang A; Lu CM; Sha MY
Emerg Microbes Infect; 2022 Dec; 11(1):250-259. PubMed ID: 34951566
[TBL] [Abstract][Full Text] [Related]
19. Neutralizing antibody titers six months after Comirnaty vaccination: kinetics and comparison with SARS-CoV-2 immunoassays.
Padoan A; Cosma C; Bonfante F; Della Rocca F; Barbaro F; Santarossa C; Dall'Olmo L; Pagliari M; Bortolami A; Cattelan A; Cianci V; Basso D; Plebani M
Clin Chem Lab Med; 2022 Feb; 60(3):456-463. PubMed ID: 34911170
[TBL] [Abstract][Full Text] [Related]
20. BNT162b2 COVID-19 vaccine and correlates of humoral immune responses and dynamics: a prospective, single-centre, longitudinal cohort study in health-care workers.
Lustig Y; Sapir E; Regev-Yochay G; Cohen C; Fluss R; Olmer L; Indenbaum V; Mandelboim M; Doolman R; Amit S; Mendelson E; Ziv A; Huppert A; Rubin C; Freedman L; Kreiss Y
Lancet Respir Med; 2021 Sep; 9(9):999-1009. PubMed ID: 34224675
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
